Annovis completes enrollment in Phase 3 Alzheimer's trial of buntanetap

Annovis Bio reported on August 14, 2026 that its pivotal Phase 3 Alzheimer's disease trial is fully enrolled with a total of 850 patients, exceeding original projections.¹ The company said the trial exceeded its original target enrollment number of 760 patients.¹

The study enrolls patients diagnosed with early Alzheimer's disease, defined by MMSE scores of 20 to 28, who also test positive for the plasma pTau217 biomarker, which the company says indicates amyloid and tau pathology in the brain.¹ The trial's design tracks cognition and function as co-primary endpoints, using additional imaging and biomarker measures, and is built to capture both a shorter-term symptomatic effect and a longer-term disease-modifying effect of buntanetap.¹ Annovis said it plans to lock the database for the 6-month symptomatic analysis in the first quarter of 2027, with that readout expected the same quarter, followed by the disease-modifying data about a year later.¹

On the Parkinson's disease side, the open-label extension study has enrolled 266 patients toward a target of 500,¹ with full enrollment projected in the fourth quarter of 2026.¹ Twenty-six clinical sites have been activated across the US.¹ An Alzheimer's open-label extension study is separately expected to begin in October 2026, according to the release.

On the corporate side, Annovis said it promoted Cheng Fang to Chief Scientific Officer, a role in which she will be responsible for clinical execution and scientific advancement of buntanetap as the company nears key regulatory milestones, per the company.¹

Financially, cash and cash equivalents totaled $18.7 million as of June 30, 2026, compared with $19.5 million at the end of 2025.¹ The company had 42.6 million shares of common stock outstanding as of June 30, 2026.¹